News

Prime Medicine wins FDA IND clearance for PM577a in vivo Prime Editor for Wilson disease

Prime Medicine (Nasdaq: PRME) announced on 23 July 2026 that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PM577a, an investigational in vivo Prime Editor for Wilson disease (WD). Together with the company's previously cleared New Zealand Clinical Trial Application, the IND clearance establishes a global Phase 1/2 clinical programme and opens participation to patients in the United States.

PM577a is the lead candidate in the PM577 family of LNP-formulated Prime Editing products designed to correct pathogenic ATP7B mutations in hepatocytes via a single intravenous infusion. It targets the H1069Q allele, which accounts for roughly 30–50% of Wilson disease-associated variants in the United States and Europe. A follow-on candidate targeting the R778L allele, the most common mutant variant in East Asian populations, is in preclinical development.

The open-label, global, first-in-human Phase 1/2 study will evaluate the safety, tolerability, biological activity and efficacy of ascending doses of PM577a in adults and adolescents with WD, initially enrolling adults clinically stable on standard-of-care therapy. Prime Medicine expects to initiate the trial in the second half of 2026, with initial clinical data anticipated in 2027.

Wilson disease is a rare inherited disorder of copper metabolism; current copper chelators and zinc salts are non-curative and require lifelong daily dosing, while liver transplantation remains the only curative option. PM577a aims to offer a one-time therapy that corrects the disease at its genetic root.

Source: BioSpace / GlobeNewswire, 23 July 2026.

More top stories